This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Glaucoma  • Statistics and Research Methods  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Harry A. Quigley, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

It has been widely stated that diabetes is a risk factor for open-angle glaucoma (OAG), but accumulating evidence suggests that the relationship may be more interesting than the textbooks and experts report.¹ The recent finding by the Ocular Hypertension Treatment Study² that early diabetes protects against the development of OAG caused the investigators to reclassify their subjects post hoc, which eliminated the statistical significance of the finding.³ Results that conflict with established ideas are often dismissed, explained away, or rejected for publication by skeptical reviewers. Diabetes is a disease, so it can't be good for us. Or can it? Examination of the association of diabetes with OAG leads to the hypothesis that early diabetes may produce a neuroprotective environment that slows retinal ganglion cell (RGC) death.

Ascertainment Bias

Historically, OAG was studied in eye clinics, where the selection of those with the disease often produces a biased sample . . . [Full Text of this Article]

No Added OAG Risk for Diabetic Patients Found in Population-Based and Longitudinal Studies

Possibility of Protectiveness of Diabetes

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Onset of Primary Open-Angle Glaucoma
Mae O. Gordon, Julia A. Beiser, James D. Brandt, Dale K. Heuer, Eve J. Higginbotham, Chris A. Johnson, John L. Keltner, J. Philip Miller, Richard K. Parrish II, M. Roy Wilson, Michael A. Kass, and for the Ocular Hypertension Treatment Study Group
Arch Ophthalmol. 2002;120(6):714-720.
ABSTRACT | FULL TEXT